Literature DB >> 16106415

Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study.

Sam M Mbulaiteye1, Elly T Katabira, Henry Wabinga, Donald M Parkin, Phillip Virgo, Robert Ochai, Meklit Workneh, Alex Coutinho, Eric A Engels.   

Abstract

Although more than 25 million people in sub-Saharan Africa have human immunodeficiency virus (HIV) infection, little is known regarding their cancer risk. We investigated cancer risk among persons with HIV/AIDS in Uganda using record-linkage. We linked records of 12,607 HIV-infected persons attending The AIDS Support Organization (TASO) in Kyadondo County from October 1988 through December 2002 to the Kampala Cancer Registry. We calculated standardized incidence ratios (SIRs) to identify increased cancer risks in the early (4-27 months after TASO registration), late (28-60 months), or combined (4-60 months) incidence periods. We identified 378 cancers (181 prevalent, 197 incident) among TASO participants. Of incident cancers, 137 (70%) were AIDS-defining cancers. Risk was increased in the early-incident period, compared to the general population, for the AIDS-defining cancers: Kaposi sarcoma (SIR 6.4, 95%CI 4.8-8.4), non-Hodgkin lymphoma (6.7, 1.8-17), and cervical carcinoma (2.4, 1.1-4.4). These three cancers were also increased in the combined periods. Risks of five non-AIDS-defining cancers were increased in the combined periods: Hodgkin lymphoma (5.7, 1.2-17) and cancers of the conjunctiva (SIR 4.0; 1.5-8.7), kidney (16, 1.8-58), thyroid (5.7, 1.1-16), and uterus (5.5, 1.5-14). Cancers of the breast, nasopharynx, and lung were increased either in the early or late incident periods only. Among 407 children, seven cancers were observed, of which five were Kaposi sarcoma. The application of a record-linkage design in Africa broadens the repertoire of epidemiological tools for studying HIV-infected populations. We confirm the increased risks of AIDS-defining cancers and report increased risks of a few non-AIDS-defining cancers.

Entities:  

Mesh:

Year:  2006        PMID: 16106415     DOI: 10.1002/ijc.21443

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  110 in total

Review 1.  Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings.

Authors:  Aggrey S Semeere; Naftali Busakhala; Jeffrey N Martin
Journal:  Curr Opin Oncol       Date:  2012-09       Impact factor: 3.645

2.  Cancer and HIV infection in referral hospitals from four West African countries.

Authors:  Antoine Jaquet; Michael Odutola; Didier K Ekouevi; Aristophane Tanon; Emmanuel Oga; Jocelyn Akakpo; Manhattan Charurat; Marcel D Zannou; Serge P Eholie; Annie J Sasco; Emmanuel Bissagnene; Clement Adebamowo; Francois Dabis
Journal:  Cancer Epidemiol       Date:  2015-09-12       Impact factor: 2.984

3.  HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data.

Authors:  Sam M Mbulaiteye; Kishor Bhatia; Clement Adebamowo; Annie J Sasco
Journal:  Infect Agent Cancer       Date:  2011-10-17       Impact factor: 2.965

4.  The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot?

Authors:  Michael L Cheng; Li Zhang; Margaret Borok; Eric Chokunonga; Charles Dzamamala; Anne Korir; Henry R Wabinga; Robert A Hiatt; D Max Parkin; Katherine Van Loon
Journal:  Cancer Epidemiol       Date:  2015-02-03       Impact factor: 2.984

5.  A Comparison of the Natural History of HPV Infection and Cervical Abnormalities among HIV-Positive and HIV-Negative Women in Senegal, Africa.

Authors:  Hilary K Whitham; Stephen E Hawes; Haitao Chu; J Michael Oakes; Alan R Lifson; Nancy B Kiviat; Papa Salif Sow; Geoffrey S Gottlieb; Selly Ba; Marie P Sy; Shalini L Kulasingam
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-05-17       Impact factor: 4.254

6.  Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.

Authors:  Eliane Rohner; Kurt Schmidlin; Marcel Zwahlen; Rana Chakraborty; Gary Clifford; Niels Obel; Sophie Grabar; Annelies Verbon; Antoni Noguera-Julian; Intira Jeannie Collins; Pablo Rojo; Norbert Brockmeyer; Maria Campbell; Geneviève Chêne; Hans Prozesky; Brian Eley; D Cristina Stefan; Alan Davidson; Cleophas Chimbetete; Shobna Sawry; Mary-Ann Davies; Azar Kariminia; Ung Vibol; Annette Sohn; Matthias Egger; Julia Bohlius
Journal:  Clin Infect Dis       Date:  2016-08-30       Impact factor: 9.079

7.  Inhibition of Kaposi's sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258.

Authors:  Qin Yan; Xinting Ma; Chenyou Shen; Xu Cao; Ninghan Feng; Di Qin; Yi Zeng; Jianzhong Zhu; Shou-Jiang Gao; Chun Lu
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

8.  A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals.

Authors:  Meredith S Shiels; Stephen R Cole; Gregory D Kirk; Charles Poole
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

9.  Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA.

Authors:  Takanobu Tagawa; Shaojian Gao; Vishal N Koparde; Mileidy Gonzalez; John L Spouge; Anna P Serquiña; Kathryn Lurain; Ramya Ramaswami; Thomas S Uldrick; Robert Yarchoan; Joseph M Ziegelbauer
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-19       Impact factor: 11.205

10.  High Cancer Burden Among Antiretroviral Therapy Users in Malawi: A Record Linkage Study of Observational Human Immunodeficiency Virus Cohorts and Cancer Registry Data.

Authors:  Marie-Josèphe Horner; Steady Chasimpha; Adrian Spoerri; Jessie Edwards; Julia Bohlius; Hannock Tweya; Petros Tembo; Franklin Nkhambule; Eddie Moffo Phiri; William C Miller; Kennedy Malisita; Sam Phiri; Charles Dzamalala; Andrew F Olshan; Satish Gopal
Journal:  Clin Infect Dis       Date:  2019-08-16       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.